Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study.

Dahl, Kirsten et al.·Lancet (London·2025·
RPEP-105892025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Key Numbers

How They Did This

Why This Research Matters

What This Study Doesn't Tell Us

Trust & Context

Original Title:
Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study.
Published In:
Lancet (London, England), 406(10499), 149-162 (2025)
Database ID:
RPEP-10589

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-10589·https://rethinkpeptides.com/research/RPEP-10589

APA

Dahl, Kirsten; Toubro, Søren; Dey, Sohan; Duque do Vale, Ruben; Flint, Anne; Gasiorek, Agnes; Heydorn, Arne; Jastreboff, Ania M; Key, Cassandra; Petersen, Signe Beck; Vegge, Andreas; Adelborg, Kasper. (2025). Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study.. Lancet (London, England), 406(10499), 149-162. https://doi.org/10.1016/S0140-6736(25)01185-7

MLA

Dahl, Kirsten, et al. "Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study.." Lancet (London, 2025. https://doi.org/10.1016/S0140-6736(25)01185-7

RethinkPeptides

RethinkPeptides Research Database. "Amycretin, a novel, unimolecular GLP-1 and amylin receptor a..." RPEP-10589. Retrieved from https://rethinkpeptides.com/research/dahl-2025-amycretin-a-novel-unimolecular

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.